CLINICAL TRIALS PROFILE FOR OBETICHOLIC ACID
✉ Email this page to a colleague
All Clinical Trials for obeticholic acid
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00570765 ↗ | Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC) | Completed | Intercept Pharmaceuticals | Phase 2 | 2008-01-17 | The primary hypothesis was that obeticholic acid (OCA) will cause a reduction in alkaline phosphatase levels in PBC participants, over a 12-week treatment period, as compared to placebo. |
| NCT01265498 ↗ | The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | 2011-03-01 | Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by changes in the nonalcoholic fatty liver disease (NAFLD) activity score (NAS). |
| NCT01473524 ↗ | Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis | Completed | Intercept Pharmaceuticals | Phase 3 | 2012-01-01 | The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on safety in participants with primary biliary cirrhosis (PBC). |
| NCT01585025 ↗ | Obeticholic Acid in Bile Acid Diarrhoea | Completed | Imperial College London | Phase 2 | 2012-04-01 | The investigators propose to develop studies of obeticholic acid (OCA) in patients with bile acid diarrhoea. OCA is a semisynthetic bile acid, also known as 6αethylchenodeoxycholic acid or INT747,and is a potent farnesoid X receptor (FXR) agonist. Preliminary data suggests that patients with bile acid diarrhoea have impaired production of the ileal hormone Fibroblast Growth Factor 19 (FGF19). FGF19 is stimulated by FXR agonists, and regulates bile acid synthesis. This study is a pilot, proof-of-concept, open-label study to investigate whether OCA can stimulate FGF19 in bile acid diarrhoea patients to provide a safe and effective treatment. |
| NCT01625026 ↗ | Obeticholic Acid in Bariatric and Gallstone Disease | Completed | Medical University of Vienna | Phase 2 | 2013-09-01 | By binding to the nuclear receptor FXR, bile acids not only regulate their own turn-over but presumably also pivotal steps in cholesterol, triglyceride and glucose metabolism as shown in laboratory animals. Obeticholic acid (OCA) is a semisynthetic bile acid with very high affinity to FXR. In a pharmacodynamic study the effects of OCA on bile acid, lipid and glucose turn-over are studied in 20 morbidly obese and 20 gallstones patents, respectively, that are administered OCA at 25 mg/day in three weeks before bariatric (BS) or gallstone (GS) surgery where in addition to blood samples also biopsies are taken from the liver and in the case of BS, omental and subcutaneous adipose tissue and in case of GS, gallbladder bile. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for obeticholic acid
Condition Name
Clinical Trial Locations for obeticholic acid
Trials by Country
Clinical Trial Progress for obeticholic acid
Clinical Trial Phase
Clinical Trial Sponsors for obeticholic acid
Sponsor Name
